Dose-dense chemotherapy for breast cancer: what does the future hold?
Within the last several decades adjuvant polychemotherapy for breast cancer has evolved with the development of anthracyclines and taxanes. Parallel to these developments, granulocyte-colony stimulating factor support has permitted the safe delivery of chemotherapy at shorter ('dose-dense') intertreatment intervals, which, as predicted by preclinical models, has further improved survival. Recently, insights into tumor biology have led the development of targeted therapies, such as trastuzumab for HER2-positive disease, and this has now been successfully incorporated into dose-dense therapy. Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents.
Morris
Patrick G
PG
Evelyn H Lauder Breast Center, 300 E 66th St, New York, NY 10065, USA. morrisp1@mskcc.org
McArthur
Heather L
HL
Hudis
Clifford
C
Norton
Larry
L
D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D005260:Female; D005544:Forecasting; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D057285:Precision Medicine
D016179:Granulocyte Colony-Stimulating Factor